Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Monolithic Power Systems Inc (MPWR) vs Sanofi SA (SNY) Price & Performance

Monolithic Power Systems IncTrade

Price performance (Past 24H)

Key statistics

Monolithic Power Systems Inc vs Sanofi SA — how do they compare? Monolithic Power Systems Inc trades at $1,391.26 (market cap $67.32B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Sanofi SA for 94 Days on average.

MPWRSNY
Market Cap
$67.32B$95.18B
Volume
826,9602,995,646
Sector
TechnologyHealth
52-Week High
$1.69K$52.34
52-Week Low
$856.96$39.51
Typical Hold Time
25 Days94 Days
Enterprise Value
$65.92B$114.48B
Dividend Yield
0.58%6.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Monolithic Power Systems Inc

Monolithic Power Systems (MPWR) trades at $1,425.98, down 3.24% on the day, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 24.5% net income margin and 21.98% ROE, though valuation metrics remain elevated at 87 P/E. Recent earnings beats and a manufacturing partnership with GlobalFoundries signal continued growth potential in AI and data center markets.

MPWR presents a compelling growth story driven by AI infrastructure demand, but faces valuation concerns and insider selling pressure. The stock's 88% buy rating consensus and $1,830 price target suggest 28% upside potential, though investors should weigh premium valuation against strong execution and market positioning.

Sanofi SA

SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.

The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MPWR
100% Buy0% Sell
Avg holding period · 25 Days
SNY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Monolithic Power Systems Inc

Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.

Read more on MPWR →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →